ArticleNeuroradiology2021
Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters.
Article in Neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.European radiology · 2025Pooled it
- Differentiation between glioma recurrence and treatment effects using amide proton transfer imaging: A mini-Bayesian bivariate meta-analysis.Frontiers in oncology · 2022Pooled it
- Unique Peritumoral Patterns Unveiled by Quantitative Multiparametric MRI and Their Diagnostic and Prognostic Value in Treated Malignant Gliomas.NMR in biomedicine · 2026Article
- Diffusion tensor image analysis along the perivascular space may serve as a potential biomarker for differentiating glioma recurrence from pseudoprogression: a preliminary study.Quantitative imaging in medicine and surgery · 2026Article
- Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Amide proton transfer-weighted (APTw) CEST MRI in clinical routine for single time point diagnosis of pseudoprogression in IDH-wildtype glioblastoma.Neuro-oncology · 2026Article
- Article
- Article
- Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer.Frontiers in neuroscience · 2024Review
- Reproducibility of APT-weighted CEST-MRI at 3T in healthy brain and tumor across sessions and scanners.Scientific reports · 2023Article
- Article
- Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma.Biomedicines · 2023Article
- A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors.Neuroradiology · 2023Article
- Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas.NMR in biomedicine · 2023Article
- Challenges and opportunities for advanced neuroimaging of glioblastoma.The British journal of radiology · 2023Review
- Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [European journal of nuclear medicine and molecular imaging · 2022Article
- Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis.Insights into imaging · 2022Review
- Volumetric Measurement of Relative CBV Using T1-Perfusion-Weighted MRI with High Temporal Resolution Compared with Traditional T2*-Perfusion-Weighted MRI in Postoperative Patients with High-Grade Gliomas.AJNR. American journal of neuroradiology · 2022Article
- Relative T2-FLAIR signal intensity surrounding residual cavity is associated with survival prognosis in patients with lower-grade gliomas.Frontiers in oncology · 2022Article
- Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.Frontiers in radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo evaluate the incremental value of amide proton transfer (APT) imaging to diffusion tensor imaging (DTI), dynamic susceptibility contrast (DSC) imaging, and dynamic contrast-enhanced (DCE) imaging in differentiating recurrent diffuse gliomas (World Health Organization grade II-IV) from treatment-induced change after concurrent chemoradiotherapy or radiotherapy.
methodsThis study included 36 patients (25 patients with recurrent gliomas and 11 with treatment-induced changes) with post-treatment gliomas. The mean values of apparent diffusion coefficient (ADC), fractional anisotropy (FA), normalized cerebral blood volume (nCBV), normalized cerebral blood flow, volume transfer constant, rate transfer coefficient, extravascular extracellular volume fraction, plasma volume fraction, and APT asymmetry index were assessed. Independent quantitative parameters were investigated to predict recurrent glioma using multivariable logistic regression. The incremental value of APT signal to other parameters was assessed by the increase of the area under the curve, net reclassification index, and integrated discrimination improvement.
resultsUnivariable analysis showed that lower ADC (p = 0.018), higher FA (p = 0.031), higher nCBV (p = 0.021), and higher APT signal (p = 0.009) were associated with recurrent gliomas. In multivariable logistic regression, the diagnostic performance of the model with ADC, FA, and nCBV significantly increased when APT signal was added, with areas under the curve of 0.87 and 0.92, respectively (net reclassification index of 0.77 and integrated discrimination improvement of 0.13).
conclusionAPT imaging may be a useful imaging biomarker that adds value to DTI, DCE, and DSC parameters for distinguishing between recurrent gliomas and treatment-induced changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.